Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERNANASDAQ:KZIANASDAQ:MEIPNASDAQ:NXTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERNAEterna Therapeutics$0.23-1.7%$0.21$0.15▼$2.63$13.60M5.612.82 million shs1.59 million shsKZIAKazia Therapeutics$3.78$3.65$2.86▼$79.00$3.81M2.49175,227 shs13,927 shsMEIPMEI Pharma$2.23+1.8%$2.07$1.46▼$4.10$14.85M0.2144,334 shs1,719 shsNXTCNextCure$0.48-2.4%$0.42$0.22▼$1.82$13.59M1.04105,179 shs69,920 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERNAEterna Therapeutics-1.70%-1.27%+8.74%-25.93%-87.83%KZIAKazia Therapeutics-0.92%+5.59%+5.29%-11.21%-68.76%MEIPMEI Pharma+1.83%+3.48%+9.31%-12.89%-23.63%NXTCNextCure-2.44%-4.63%+4.06%-37.83%-69.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERNAEterna Therapeutics0.718 of 5 stars0.03.00.00.01.81.70.6KZIAKazia Therapeutics3.3035 of 5 stars3.53.00.00.03.80.00.0MEIPMEI Pharma2.0667 of 5 stars0.03.00.04.13.30.81.3NXTCNextCure4.2947 of 5 stars3.53.00.04.32.41.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERNAEterna Therapeutics 0.00N/AN/AN/AKZIAKazia Therapeutics 3.00Buy$57.501,421.16% UpsideMEIPMEI Pharma 2.00HoldN/AN/ANXTCNextCure 3.00Buy$3.50622.69% UpsideCurrent Analyst Ratings BreakdownLatest KZIA, MEIP, NXTC, and ERNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/17/2025NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.003/7/2025NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $3.00(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERNAEterna Therapeutics$535K26.24N/AN/A$0.41 per share0.55KZIAKazia Therapeutics$2.31M1.65N/AN/A($1.97) per share-1.92MEIPMEI Pharma$65.30M0.23$5.07 per share0.44$3.32 per share0.67NXTCNextCureN/AN/AN/AN/A$4.10 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERNAEterna Therapeutics-$21.67M-$8.31N/A∞N/A-7,513.88%N/A-117.48%8/11/2025 (Estimated)KZIAKazia Therapeutics-$17.56MN/A0.00∞N/AN/AN/AN/AN/AMEIPMEI Pharma$17.78M-$4.75N/AN/AN/AN/A-84.92%-67.53%N/ANXTCNextCure-$62.72M-$1.76N/AN/AN/AN/A-62.50%-53.67%8/7/2025 (Estimated)Latest KZIA, MEIP, NXTC, and ERNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q3 2025MEIPMEI PharmaN/A-$0.39N/A-$0.39N/AN/A5/1/2025Q1 2025NXTCNextCure-$0.40-$0.39+$0.01-$0.39N/AN/A3/6/2025Q4 2024NXTCNextCure-$0.34-$0.41-$0.07-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERNAEterna TherapeuticsN/AN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/AN/AMEIPMEI PharmaN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERNAEterna TherapeuticsN/A0.480.48KZIAKazia TherapeuticsN/A0.240.24MEIPMEI PharmaN/A10.6610.66NXTCNextCureN/A9.079.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERNAEterna Therapeutics70.55%KZIAKazia Therapeutics30.89%MEIPMEI Pharma52.38%NXTCNextCure42.65%Insider OwnershipCompanyInsider OwnershipERNAEterna Therapeutics1.50%KZIAKazia Therapeutics1.00%MEIPMEI Pharma3.12%NXTCNextCure17.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERNAEterna Therapeutics1062.36 million5.17 millionNo DataKZIAKazia Therapeutics121.01 million4.99 millionOptionableMEIPMEI Pharma1006.66 million6.46 millionOptionableNXTCNextCure9028.05 million24.28 millionOptionableKZIA, MEIP, NXTC, and ERNA HeadlinesRecent News About These CompaniesNextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ...May 30 at 11:03 PM | morningstar.comNextCure, Inc. and LigaChem Biosciences Announce Phase 1 Study of LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, to be Presented at ASCO 2025May 30 at 11:03 PM | nasdaq.comNextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024May 30 at 12:17 AM | insidermonkey.comNextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025May 29 at 4:05 PM | globenewswire.comNextCure Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 2, 2025 | taiwannews.com.twNextCure Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 1, 2025 | globenewswire.comNextCure to Present at 24th Annual Needham Virtual Healthcare ConferenceApril 4, 2025 | globenewswire.comH.C. Wainwright says competitor data builds optimism for NextCure’s LNCB74March 17, 2025 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for NextCure (NXTC)March 8, 2025 | markets.businessinsider.comNextCure Reports 2024 Financials and Strategic ProgressMarch 7, 2025 | tipranks.comNextCure, Inc. Completes First Cohort of Phase 1 Trial for LNCB74 and Plans for Backfill CohortsMarch 6, 2025 | quiverquant.comNextCure Provides Business Update and Reports Full Year 2024 Financial ResultsMarch 6, 2025 | globenewswire.comNextCure stock plunges to 52-week low, hits $0.69February 12, 2025 | msn.comNextCure, Inc. Doses First Patient in Phase 1 Study of B7-H4-Targeting Antibody-Drug Conjugate LNCB74January 10, 2025 | quiverquant.comNextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple CancersJanuary 10, 2025 | globenewswire.comNextCure stock hits 52-week low at $0.99 amid market challengesDecember 18, 2024 | investing.comNextCure, Inc. Announces FDA Acceptance of IND Application for Phase 1 Trial of B7-H4-targeting ADC LNCB74December 10, 2024 | quiverquant.comNextCure Announces Acceptance of IND Application for LNCB74December 10, 2024 | globenewswire.comNextCure to Participate in the 36th Annual Piper Sandler Healthcare ConferenceNovember 26, 2024 | globenewswire.comPreclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis ImperfectaNovember 19, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKZIA, MEIP, NXTC, and ERNA Company DescriptionsEterna Therapeutics NASDAQ:ERNA$0.23 0.00 (-1.70%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.23 +0.00 (+0.40%) As of 05/30/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Kazia Therapeutics NASDAQ:KZIA$3.82 +0.04 (+1.03%) As of 05/30/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.MEI Pharma NASDAQ:MEIP$2.23 +0.04 (+1.83%) Closing price 05/30/2025 03:50 PM EasternExtended Trading$2.18 -0.05 (-2.24%) As of 05/30/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.NextCure NASDAQ:NXTC$0.48 -0.01 (-2.44%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.51 +0.02 (+4.89%) As of 05/30/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
